UK health authorities are testing a groundbreaking device that is designed to improve the way progesterone is absorbed in women at risk of miscarriage. Named Callavid, the small, tampon-shaped device could soon replace the current use of vaginal pessaries, which are often uncomfortable and messy, in administering this vital hormone.Why Is Progesterone Important?Progesterone plays a crucial role in early pregnancy, helping to prepare and support the womb for a growing baby. For women who have previously experienced miscarriage and early bleeding in subsequent pregnancies, progesterone treatment is recommended. However, the current delivery method is far from ideal—prone to leakage and often uncomfortable—leaving many women feeling distressed during an already anxious time.That is where Callavid comes in. Developed by Calla Lily Clinical Care, the device is designed to deliver progesterone more effectively and with greater comfort. Experts hope it could significantly ease the emotional and physical burden faced by thousands of women every year. "At a time when women are going through one of the most distressing moments of their lives, we want to offer something that feels dignified, supportive, and effective," said Lara Zibners, co-founder of Calla Lily Clinical Care. She called the recent £1 million funding from the National Institute for Health and Care Research a major step forward. The grant will allow the device to enter in-person trials, moving it closer to being widely available for use.Over 1, 00,000 Women Could BenefitUniversity Hospitals Coventry and Warwickshire (UHCW) NHS Trust is leading the clinical trial. According to their estimates, more than 150,000 women in the UK could benefit from this alternative method of progesterone delivery.Beyond the emotional impact, the innovation also holds promise for reducing costs to the healthcare system. Current methods are not only inefficient for some women but also contribute to an estimated £236 million annual burden on the NHS, according to health economists.ALSO READ: What Happens To Your Body When You Quit Carbs For 7 DaysProfessor Siobhan Quenby, a specialist in obstetrics and reproductive health at UHCW, emphasised the broader importance of the trial. “We know how frightening and heartbreaking it can be to experience early bleeding in pregnancy, especially for those who have experienced miscarriage before,” she said. “Through this innovation, one which is being pioneered right here in the UK, I believe there is potential to transform women's experiences—not just physically, but emotionally too.”More Research Is NeededWhile more research and testing are needed before Callavid becomes widely available, the early promise it shows is encouraging. With progesterone therapy being such a vital component of care for women at risk of miscarriage, a more efficient and compassionate delivery method could not only improve clinical outcomes but also bring some peace of mind during a deeply vulnerable time.As trials progress, both healthcare professionals and women alike are watching with hope that Callavid might soon become a new standard in early pregnancy care.ALSO READ: Peripartum Cardiomyopathy: What Kills Women During Childbirth?